Use of clomipramine as chemotherapy of the chronic phase of Chagas disease.

Chagas infection is a major endemic disease affecting Latin American countries. The persistence of Trypanosoma cruzi generates a chronic inflammatory reactivity that induces an immune response directed to the host's tissues. The effectiveness of the treatment in the chronic phase is still unsatisfactory due, amongst other reasons, to the collateral effects of the drugs used. We investigated the effect of clomipramine, a tricyclic antidepressant that, when used as a treatment of T. cruzi-chronically infected mice, inhibits trypanothione reductase, an exclusive and vital enzyme of T. cruzi. Clomipramine improved survival (P<0.05) by diminishing the parasite intensity as demonstrated by PCR studies in the heart and skeletal muscle, and significantly prevented the evolution to fibrosis of the inflammatory infiltrates. Clomipramine could be a good candidate for the treatment of chronic Chagas disease.

Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.

Alternative strategies are being designed to identify candidates among drugs already available on the market that could be used in combination to improve the efficacy of Chagas disease treatment. This work evaluates the effect of the association of clomipramine (CLO) with benznidazole (BZN) for the treatment of experimental Chagas disease in the acute stage, in Swiss albino mice infected with Trypanosoma cruzi Tulahuen strain. Infected mice were treated with CLO 5mg/kg/day and BZN 50 and 100mg/kg/day, each separately or together. Efficacy of the treatment was evaluated through parasitemia, survival, electrocardiography, histopathological studies, serological and PCR assays at 90 days post-infection (dpi). All treatments significantly (P<0.05) reduced mortality and decreased parasitemia. Histopathological analysis of liver and kidneys of mice treated with CLO and the drug combination showed less injury than mice treated only with BZN. The lower dose of BZN (50mg/kg/day) combined with CLO showed the same efficacy as the habitual dose of BZN (100mg/kg/day) combined with CLO. The therapeutic results from the combination of BZN with CLO presented lesser side effects than the treatment with BZN.

[Importance of host sex in the development of trypanosoma cruzi infection]. / Importancia del sexo del huésped en el desarrollo de la infección por Trypanosoma Cruzi.

Multiple factors, both dependent on the host and the parasite are involved in determining resistance or susceptibility to infection with T. cruzi, but the influence of the sex of the host is a factor that has not been clearly established. In this paper we analyzed the influence of this factor upon the infected individuals. We used Swiss albino mice infected with 50 trypomastigotes / mouse of T. cruzi, strain Tulahuen: males (n = 73) and females (n = 64). The highest parasitemia was detected on day 21 post-infection (pi) in both males and females and became negative on day 56 pi, and males exhibited significantly higher levels of parasitemia. The highest mortality occurred between day 21 and day 28 pi; by day 270 pi (chronic stage) one male (3%) survived every 7.6 females (23%). In skeletal muscle of male and female mice on days 90, 180 and 270 pi, lympho-monocitary infiltrates were found nests of amastigotes, whereas the myocardium of these animals showed inflammatory infiltrates only. We conclude that males showed greater susceptibility to infection and higher mortality than females in this mouse model infected with T. cruzi, Tulahuen strain, but the characteristics of the infection and cardiomyopathy development are similar in nature.